Stock Market Update, Feb. 23: ImmunityBio Rises Following 700% Increase in Anktiva Revenue
ImmunityBio’s Stock Update ImmunityBio (NASDAQ: IBRX) closed on Monday at $9.83, marking a 12.99% increase. This jump follows impressive financial results where its revenue surged by 700% and losses narrowed. Investors are now keenly observing upcoming approvals and global partnerships, which may impact continued demand. Trading volume reached 85.8 million shares, significantly above the three-month […]